Whole-exome and whole-genome sequencing in chronic lymphocytic leukemia: new biomarkers to target

Pharmacogenomics. 2020 Aug;21(13):957-962. doi: 10.2217/pgs-2020-0022. Epub 2020 Aug 17.

Abstract

Many biomarkers indicate prognosis in chronic lymphocytic leukemia; such as fluorescence in situ hybridization testing: 17p or 11q deletions have a worse prognosis than trisomy 12, 13q deletion or normal result, or the mutational status of the immunoglobulin heavy chain (IGHV): unmutated IGHV have a worse prognosis than mutated IGHV. Recently, many gene mutations (TP53, NOTCH1 etc.,) have been linked to a worse prognosis. With the new era of high-throughput sequencing, it has become easier to study gene mutations and their implication in predicting prognosis. In this review, we aim to review all the studies that performed whole-exome sequencing or whole-genome sequencing on chronic lymphocytic leukemia cells and explore the implication of various genes in disease prognosis.

Keywords: chronic lymphocytic leukemia; mutations; whole-exome sequencing; whole-genome sequencing.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics*
  • Exome Sequencing / methods
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Mutation / genetics
  • Prognosis
  • Trisomy / genetics

Substances

  • Biomarkers, Tumor